149 related articles for article (PubMed ID: 8448065)
1. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.
Wu D; Otton SV; Sproule BA; Busto U; Inaba T; Kalow W; Sellers EM
Br J Clin Pharmacol; 1993 Jan; 35(1):30-4. PubMed ID: 8448065
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.
Jacqz-Aigrain E; Funck-Brentano C; Cresteil T
Pharmacogenetics; 1993 Aug; 3(4):197-204. PubMed ID: 8220439
[TBL] [Abstract][Full Text] [Related]
3. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.
Kerry NL; Somogyi AA; Bochner F; Mikus G
Br J Clin Pharmacol; 1994 Sep; 38(3):243-8. PubMed ID: 7826826
[TBL] [Abstract][Full Text] [Related]
4. Inhibition by fluoxetine of cytochrome P450 2D6 activity.
Otton SV; Wu D; Joffe RT; Cheung SW; Sellers EM
Clin Pharmacol Ther; 1993 Apr; 53(4):401-9. PubMed ID: 8477556
[TBL] [Abstract][Full Text] [Related]
5. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4.
Iribarne C; Dréano Y; Bardou LG; Ménez JF; Berthou F
Toxicology; 1997 Feb; 117(1):13-23. PubMed ID: 9020195
[TBL] [Abstract][Full Text] [Related]
6. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
[TBL] [Abstract][Full Text] [Related]
7. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites.
Ching MS; Blake CL; Ghabrial H; Ellis SW; Lennard MS; Tucker GT; Smallwood RA
Biochem Pharmacol; 1995 Sep; 50(6):833-7. PubMed ID: 7575645
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.
Otton SV; Schadel M; Cheung SW; Kaplan HL; Busto UE; Sellers EM
Clin Pharmacol Ther; 1993 Nov; 54(5):463-72. PubMed ID: 7693389
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes.
Le Guellec C; Lacarelle B; Catalin J; Durand A
Cancer Chemother Pharmacol; 1993; 32(6):491-5. PubMed ID: 8258200
[TBL] [Abstract][Full Text] [Related]
10. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes.
Iribarne C; Berthou F; Baird S; Dréano Y; Picart D; Bail JP; Beaune P; Ménez JF
Chem Res Toxicol; 1996 Mar; 9(2):365-73. PubMed ID: 8839037
[TBL] [Abstract][Full Text] [Related]
11. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6.
Masimirembwa CM; Hasler JA; Johansson I
Eur J Clin Pharmacol; 1995; 48(1):35-8. PubMed ID: 7621845
[TBL] [Abstract][Full Text] [Related]
13. Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro.
Wu D; Otton SV; Morrow P; Inaba T; Kalow W; Sellers EM
J Pharmacol Exp Ther; 1993 Aug; 266(2):715-9. PubMed ID: 8355202
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine.
Kirkwood LC; Nation RL; Somogyi AA
Br J Clin Pharmacol; 1997 Dec; 44(6):549-55. PubMed ID: 9431830
[TBL] [Abstract][Full Text] [Related]
15. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism.
Liu Z; Mortimer O; Smith CA; Wolf CR; Rane A
Br J Clin Pharmacol; 1995 Jan; 39(1):77-80. PubMed ID: 7756104
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA
Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095
[TBL] [Abstract][Full Text] [Related]
18. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
Coleman T; Ellis SW; Martin IJ; Lennard MS; Tucker GT
J Pharmacol Exp Ther; 1996 May; 277(2):685-90. PubMed ID: 8627546
[TBL] [Abstract][Full Text] [Related]
19. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone.
Moody DE; Alburges ME; Parker RJ; Collins JM; Strong JM
Drug Metab Dispos; 1997 Dec; 25(12):1347-53. PubMed ID: 9394023
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation.
Schmider J; Greenblatt DJ; von Moltke LL; Harmatz JS; Shader RI
Br J Clin Pharmacol; 1996 Apr; 41(4):339-43. PubMed ID: 8730981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
